| 刘一诚 戴彭辰 何成诗 腾柱国 王超群.参一胶囊对晚期NSCLC 维持治疗的临床研究[J].,2016,16(9):1715-1717 |
| 参一胶囊对晚期NSCLC 维持治疗的临床研究 |
| Clinical Research of Ginsenoside Rg3 in the Maintenance Treatment ofAdvanced NSCLC |
| |
| DOI： |
| 中文关键词: 非小细胞肺癌 参一胶囊 维持治疗 疗效 |
| 英文关键词: Non-small cell lung cancer Ginsenoside Rg3 Maintenance treatment Efficacy |
| 基金项目: |
|
| 摘要点击次数: 810 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨晚期非小细胞肺癌（NSCLC）患者化疗获益后采用参一胶囊维持治疗的临床疗效。方法：选择2010 年11 月到
2014 年11 月在我院经一线化疗后疗效评价无病情进展的120 例晚期NSCLC 患者，随机分为对照组（n=60）和实验组（n=60）。对
照组仅接受定期随访观察，实验组采用参一胶囊维持治疗，比较两组患者治疗后的临床疗效、治疗前后免疫功能、生活质量的变
化及不良反应的发生情况。结果：实验组患者的疾病控制率（DCR）明显高于对照组（P<0.05）。治疗后，两组患者各免疫功能检测指
标均低于治疗前，且实验组明显大于对照组（P>0.05）。治疗后，实验组KPS 评分提高率明显高于对照组（P<0.05）。整个维持治疗
过程中无治疗相关性死亡。结论：晚期NSCLC 患者在化疗后采用参一胶囊维持治疗，可显著提高患者免疫功能、改善生活质量，
且安全性良好，疗效显著，值得在临床上推广应用。 |
| 英文摘要: |
| Objective:To investigate the clinical efficacy of ginsenoside Rg3 in maintenance treatment of patients with advanced
non-small cell lung cancer(NSCLC) after chemotherapy.Methods:A total of 120 patients with advanced NSCLC, who were treated with
the first-line chemotherapy and without progression disease in Affiliated Hospital of Chengdu University of Traditional Chinese from
November 2010 to November 2014, were selected and randomly divided into experiment group (n=60) and control group (n=60). The
control group was only regularly followed up and observed, while the experiment group was maintained with ginsenoside Rg3. Then the
clinical efficacy, the changes of immune indexes and the quality of life before and after treatment and the incidence of adverse reactions
in the two groups were compared.Results:The disease control rate (DCR) of experimental group was obviously higher than that of control
group (P<0.05). The immune indexes of two groups after treatment were lower than before treatment, meanwhile, the indexes of experimental
group were significantly higher than those of control group (P<0.05). The improvement rate of KPS score in the experimental
group after treatment was significantly higher than that in the control group (P<0.05). There was no treatment-related death during the
whole maintenance treatment.Conclusion:Using ginsenoside Rg3 in the maintenance treatment of patients with advanced NSCLC after
chemotherapy can improve the immune function and increase the quality of life, with good safety and efficacy,which is worthy of clinical
promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
